P. Chung

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

S. Steinberg, S. Grupp, B. Wood, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of children and young adults with T‐cell acute lymphoblastic leukemia/lymphoma who present in critical status

Yimei Li, S. Rheingold, P. Chung, 2022, Pediatric blood & cancer.

Isolation of embryonic stem cells from enhanced green fluorescent protein-transgenic mouse and their survival in the cochlea after allotransplantation.

H. Shim, T. Choi, S. Shin, 2008, Cytotherapy.

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

S. Steinberg, S. Grupp, B. Wood, 2022, Blood advances.

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

S. Steinberg, S. Grupp, T. Laetsch, 2022, Blood advances.

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

S. Steinberg, T. Laetsch, M. Pulsipher, 2020 .

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

S. Steinberg, S. Grupp, B. Wood, 2021, Blood.

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax

S. Tasian, L. Niswander, P. Chung, 2023, Haematologica.